Oak Grove Capital LLC Sells 450 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Oak Grove Capital LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,580 shares of the biopharmaceutical company’s stock after selling 450 shares during the quarter. Oak Grove Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $1,354,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of REGN. Activest Wealth Management raised its holdings in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $27,000. Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $32,000. Finally, SouthState Corp grew its position in Regeneron Pharmaceuticals by 550.0% in the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 44 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $802.35.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $577.95 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm’s 50-day simple moving average is $576.32 and its 200-day simple moving average is $562.53. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $943.83. The firm has a market cap of $61.26 billion, a P/E ratio of 14.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the business earned $11.56 EPS. The firm’s revenue was up 3.6% on a year-over-year basis. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.